- Previous Close
8.20 - Open
9.04 - Bid --
- Ask --
- Day's Range
8.39 - 9.04 - 52 Week Range
4.11 - 28.68 - Volume
7,699 - Avg. Volume
42,059 - Market Cap (intraday)
55.342M - Beta (5Y Monthly) 2.88
- PE Ratio (TTM)
-- - EPS (TTM)
-16.38 - Earnings Date Mar 31, 2025 - Apr 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
107.00
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
www.fortebiorx.comRecent News: FBRX
View MorePerformance Overview: FBRX
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FBRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FBRX
View MoreValuation Measures
Market Cap
52.43M
Enterprise Value
36.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-67.66%
Return on Equity (ttm)
-137.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-34.2M
Diluted EPS (ttm)
-16.38
Balance Sheet and Cash Flow
Total Cash (mrq)
16.36M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-18.36M